Zoetis Stock Rises 2.43% in Three Days, Trading Volume Drops to 216th Rank

On June 2, 2025, Zoetis (ZTS) closed at $0.47, marking a three-day consecutive rise with a total increase of 2.43%. The trading volume was $430 million, a 53.38% decrease from the previous day, ranking 216th in the day's market activity.

Zoetis has introduced AI Masses, a new AI-powered analysis technology designed to provide rapid and accurate in-clinic screening of common lymph node and skin/subcutaneous lesions. This innovation enhances the Vetscan Imagyst analyzer, making it the most advanced veterinary AI analyzer globally. AI Masses leverages deep learning algorithms to identify and classify these lesions, offering real-time insights that improve accessibility to care for pet owners and veterinary patients. The technology is set to be showcased at the 40th World Veterinary Association Congress in Washington, D.C., from July 18-22, 2025.

AI Masses is part of Zoetis' broader digital cytology offering, which includes expert clinical pathologist reviews via Digital Cytology and Add-on Expert Review. This capability is expected to streamline diagnostic processes and reduce workflow disruptions, allowing veterinary practices to make timely, individualized treatment decisions. The new feature will be available on all Vetscan Imagyst analyzers in North America starting June 2, 2025.

Abhay Nayak, President of Global Diagnostics at Zoetis, highlighted the significance of AI Masses in empowering veterinary teams to make informed decisions, thereby reducing waiting times and alleviating stress for pet owners. The technology's comprehensive digital cytology capabilities and flexible result delivery options are designed to support veterinary practices in managing cases with confidence.